Engineering probiotic consortia to improve chemotherapy tolerance and reduce toxicity in breast cancer patients: a new frontier in supportive precision oncology.

Obeagu EI

Open source

DOI
10.3389/or.2026.1909404
Published
2026
Container
Oncology reviews
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/or.2026.1909404,
  title = {Engineering probiotic consortia to improve chemotherapy tolerance and reduce toxicity in breast cancer patients: a new frontier in supportive precision oncology.},
  author = {Obeagu EI},
  year = {2026},
  journal = {Oncology reviews},
  doi = {10.3389/or.2026.1909404},
  url = {https://doi.org/10.3389/or.2026.1909404}
}

RIS

TY  - JOUR
TI  - Engineering probiotic consortia to improve chemotherapy tolerance and reduce toxicity in breast cancer patients: a new frontier in supportive precision oncology.
AU  - Obeagu EI
PY  - 2026
JO  - Oncology reviews
DO  - 10.3389/or.2026.1909404
UR  - https://doi.org/10.3389/or.2026.1909404
ER  - 

APA

EI, O. (2026). Engineering probiotic consortia to improve chemotherapy tolerance and reduce toxicity in breast cancer patients: a new frontier in supportive precision oncology.. Oncology reviews. https://doi.org/10.3389/or.2026.1909404

Source records